BEIJING (Reuters) – Health authorities of the Republic of Peru have approved a Phase 3 clinicla trial for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutial giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates.
Phase 3 trials, which usually inovlve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
(Reporting by Roxanne Liu and Tony Munroe in Beijing; Editing Shri Navaratnam)
